HDAC9 and hepatocellular carcinoma: Finally, CDK inhibitor (CDKi) Aminopurvalanol-a and HDAC inhibitor (HDACi) NCH-51 were selected to conduct in vitro experiments to further test their potential role in HCC treatment.